RefleXion, the pioneer in SCINTIX® autonomous radiotherapy, has announced FDA clearance of its next-generation X2 platform that introduces significant technical advancements:
• Expanded PET Field-of-View: The X2 increases the PET field of view from 5 cm to more than 20 cm, enabling the system to capture biologic activity across a substantially larger portion of patient anatomy.
• Increased Sensitivity: The X2 platform is designed with a 20-fold increase in PET sensitivity, facilitating advanced treatment algorithms and potentially broadening patients eligible for SCINTIX therapy.
Ad Statistics
Times Displayed: 16536
Times Visited: 38 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
• Clinical Foundation: These enhancements build upon a clinical foundation of more than 500 SCINTIX therapy procedures delivered to date.
SCINTIX therapy transforms diagnostic PET tracers into real-time treatment bioguides. This innovation combines the precision of molecular targeting with the effectiveness of radiotherapy for treating lung and bone tumors arising from primary or metastatic cancers. Currently cleared for use with FDG, RefleXion is investigating a portfolio of tracers, including PSMA-targeted agents for prostate cancer, and a proprietary FAP tracer for pan-cancer applications.
RefleXion will host live simulations of its technology throughout the exhibition. We invite physicians and clinical partners to Booth 2558 to learn how the X2 platform transforms FDG into a theranostic guide for external-beam radiotherapy. Learn more at www.reflexion.com.
